Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma

• Main Authors: Yuen, J.S.P, Sim, M.Y, Sim, H.G, Chong, T.W, Lau, W.K.O, Cheng, C.W.S, Ong, R.W, Huynh, H
• Other Authors: MEDICINE
• Format: Article
• Published: 2020
• Subjects: BIM protein; cyclin B1; cyclin dependent kinase 2; mitogen activated protein kinase; p70s6k protein; p90rsk protein; platelet derived growth factor beta receptor; protein; protein BAD; protein p27; selumetinib; sorafenib; survivin; unclassified drug; vasculotropin receptor 2; angiogenesis; animal experiment; animal model; animal tissue; antiangiogenic activity; antineoplastic activity; apoptosis; article; cancer combination chemotherapy; cancer inhibition; cell cycle arrest; cell cycle G0 phase; cell cycle G1 phase; cell cycle G2 phase; cell cycle S phase; cell migration; cell proliferation; concentration response; controlled study; down regulation; drug dose reduction; drug efficacy; human; human cell; immunoblotting; immunohistochemistry; kidney carcinoma; low drug dose; male; microvasculature; mouse; nonhuman; priority journal; protein phosphorylation; retinoblastoma; tumor volume; tumor xenograft; upregulation; Western blotting; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzimidazoles; Carcinoma, Renal Cell; Cell Proliferation; Humans; Kidney Neoplasms; Mice; Mitogen-Activated Protein Kinase 3; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Processing, Post-Translational; Pyridines; Receptor, Platelet-Derived Growth Factor beta; Tumor Burden; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/180827
• Institution: National University of Singapore

10.3892/ijo.2012.1494